Biodexa Pharmaceticals (BDRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) has a cash flow conversion efficiency ratio of -0.204x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.33 Million) by net assets ($11.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BDRX market cap overview for the company's overall valuation and market capitalisation.
Biodexa Pharmaceticals - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Biodexa Pharmaceticals's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biodexa Pharmaceticals Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biodexa Pharmaceticals ranked by their cash flow conversion efficiency. See BDRX operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanti Overseas (India) Limited
NSE:SHANTI
|
-0.015x |
|
Onconetix Inc
NASDAQ:ONCO
|
-0.181x |
|
Aesthetic Medical International Holdings Group Limited
NASDAQ:PAIYY
|
-0.054x |
|
Creo Medical Group PLC
LSE:CREO
|
-0.684x |
|
Midsona AB (publ)
ST:MSON-A
|
0.048x |
|
RightBridge Ventures Group AB
ST:RIGHTB
|
0.172x |
|
ARCTIC BLUE BEVERAGES AB
F:U5L
|
0.143x |
|
Kollect on Demand Holding Ab
ST:KOLL
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Biodexa Pharmaceticals (2012–2025)
The table below shows the annual cash flow conversion efficiency of Biodexa Pharmaceticals from 2012 to 2025. View Biodexa Pharmaceticals (BDRX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $11.38 Million | $-5.39 Million | -0.474x | +67.84% |
| 2024-12-31 | $8.32 Million | $-12.26 Million | -1.473x | -0.97% |
| 2023-12-31 | $4.68 Million | $-6.83 Million | -1.459x | +34.54% |
| 2022-12-31 | $3.16 Million | $-7.05 Million | -2.229x | -287.79% |
| 2021-12-31 | $10.45 Million | $-6.01 Million | -0.575x | +58.48% |
| 2020-12-31 | $6.72 Million | $-9.30 Million | -1.384x | -317.29% |
| 2019-12-31 | $19.56 Million | $-6.49 Million | -0.332x | +58.25% |
| 2018-12-31 | $16.92 Million | $-13.45 Million | -0.795x | -112.75% |
| 2017-12-31 | $34.68 Million | $-12.95 Million | -0.374x | -30.52% |
| 2016-12-31 | $45.72 Million | $-13.09 Million | -0.286x | -8.03% |
| 2015-12-31 | $46.89 Million | $-12.42 Million | -0.265x | -103.91% |
| 2014-12-31 | $41.99 Million | $-5.46 Million | -0.130x | +97.77% |
| 2013-12-31 | $760.00K | $-4.44 Million | -5.837x | -1601.94% |
| 2012-12-31 | $-8.28 Million | $-3.22 Million | 0.389x | -- |
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more